Hong Kong, Germany Town, Maryland, and Suzhou, China, March 12, 2024 /PRNewswire/ -- Sirnaomics Ltd.(“Company”, stock code: 2257.HK, together with its subsidiaries, collectively the “Group” or “SirnaOmics”) is an industry-leading biopharmaceutical company focused on exploring and developing RNAi therapies. Sirnaomics announced today that it will be invited to attend the 2024 OPT Summit (Oligonucleotide and mRNA Therapy Summit) and share the latest developments in the company's innovative dual-targeted MurNA delivery platform based on GalNAC-RNAi therapy and its related pipeline project. The 2024 OPT Summit will be held in Boston, USA from March 13 to 14, 2024.
Based on advances in single targets for galAhead MxRNA, siRNAomics has developed a proprietary delivery platform galAhead mURNA based on RNAi therapy, which can simultaneously inhibit multiple genes. Like mxRNA, galaAhead MURNA uses the GalNAc ligand, as a clinically proven RNAi trigger delivered to hepatocytes in the liver to treat liver-related diseases. The muRNA concept therapy uses a unique RNAi design, composed of a double chain containing two antisense chains and two complementary adaptive chains, and their specific engineered variable points. The cleavage point allows muRNA to be broken down into two separate RNAi triggers in the lysosome pathway after delivery to the cell, while individualized RNAi triggers can target each target gene separately.
From a biological point of view, muRNA concept therapy can also allow physiological functions to function as normal when regulating overactivated biological pathways. In another case, muRNA can simultaneously target two or more unrelated indications, and patient groups with these indications often coexist with multiple diseases. GalaAhead mRNA therapy provides a new and inspiring direction for the RNAi field, promising safe and long-lasting treatments for groups of patients with unmet medical needs.
2024 OPT Summit (Oligonucleotide & mRNA Therapeutics Congress) presentation details
- Lecture topic: GalaHead: A Novel Therapeutic GalNAC-RNAi Delivery Platform That Can Downregulate Single Genes or Multiple Genes
- Speaker: Dr. Jim Weterings, VP of RNA Therapy and Delivery R&D, Sirnaomics
- The content of the speech:
- Introducing GALAHEAD - siRNAomics Novel GalNAc-RNAi Delivery Platform
- Validation of GalAhead mRNA technology in vivo and in vitro
- Progress of projects related to muRNA dual-target design
Dr. Wetering will attend and host the summit theme forum at 3:40 p.m. on the same day as the summit chairman, and give an opening speech on the efficacy and future application of RNA therapy.
regardingSirnaomics Ltd. (Stock code: 2257)
siRNAomics is an RNA therapy biopharmaceutical company. The company's candidate products are in the clinical and preclinical stages, focusing on exploring and developing innovative drugs to treat indications with medical needs and huge market opportunities. siRNAomics is the first clinical-stage RNA therapy biopharmaceutical company with significant market positions in both Asia and the US. With its proprietary delivery technology: a peptide nanoparticle delivery platform and a second-generation GalNAc conjugate delivery platform, the Group has established a very rich pipeline of drug candidates. With many successes in the company's STP705 and STP707 clinical projects, siRNAomics is currently in an international leading position in promoting RNAi drugs for tumor treatment. STP122g is the first drug candidate for GALAhead technology to enter clinical development. With the establishment of the Sirnomics clinical production facility, the Group is currently making the leap from a biotech company to a biopharmaceutical company. For more information about the company, please visit: